ChronoScale Holdings Corporation (CHRN) Targets $1B Run-Rate by Q3 2027; Sells Ekso Unit

ChronoScale (CHRN) expects to reach $1B annualized revenue run-rate by Q3 2027, driven by new and expanded AI infrastructure agreements. The company also completed the sale of its Ekso Bionics unit. According to the company, this target is subject to risks and depends on financing, power security, and on-time deployments.

Original reporting
Published Oct 1, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ChronoScale Holdings Corporation (CHRN) Targets $1B Run-Rate by Q3 2027; Sells Ekso Unit — source image
Decision brief

The 30-second read

$CHRNNeutralMed
01

Why it matters

The announced guidance and unit sale provide fresh data points for valuation models and may trigger re‑rating by analysts.

02

Market read

New corporate guidance and divestiture create a fresh catalyst for CHRN, influencing short‑term sentiment and long‑term valuation.

03

What to watch

Details on financing, power procurement, and timing of deployments are not disclosed, adding uncertainty.

Relevance 7/10Novelty 7/10Timing: today

Background

ChronoScale is a post‑combination AI infrastructure scale‑up seeking to anchor investor expectations on future revenue capacity.

Company-level read

Ticker impact

$CHRNNeutralMedium confidence
Context

ChronoScale announced a $1 billion annualized run‑rate target by Q3 2027 and disclosed the sale of its Ekso Bionics business unit.

Expected impact

potential upside if the run‑rate materializes, but near‑term pressure as investors assess execution risk.

Evidence & confidence

The new revenue target is a forward‑looking metric; market reaction will depend on credibility of execution and proceeds from the unit sale.

Market effects

Highlights growing AI‑infrastructure demand, may benefit peer AI‑hardware and cloud providers.

U.S. tech sector focus; limited broader regional effect.

Modest, as the guidance pertains to a niche AI infrastructure player.

Counterpoint

The $1 billion run‑rate may be overly optimistic; execution risk could lead to share downside.

Key entities

  • ChronoScale Holdings Corporation

    AI infrastructure provider targeting $1 billion run‑rate.

  • Ekso Bionics

    Divested unit sold by ChronoScale.

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.